JP2012255007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012255007A5
JP2012255007A5 JP2012176112A JP2012176112A JP2012255007A5 JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5 JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5
Authority
JP
Japan
Prior art keywords
mutein
amino acid
acid sequence
peg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012176112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012255007A (ja
JP5774557B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012255007A publication Critical patent/JP2012255007A/ja
Publication of JP2012255007A5 publication Critical patent/JP2012255007A5/ja
Application granted granted Critical
Publication of JP5774557B2 publication Critical patent/JP5774557B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012176112A 2009-08-05 2012-08-08 リポカリン突然変異タンパク質の制御放出製剤 Expired - Fee Related JP5774557B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23136509P 2009-08-05 2009-08-05
US61/231,365 2009-08-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012523344A Division JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤

Publications (3)

Publication Number Publication Date
JP2012255007A JP2012255007A (ja) 2012-12-27
JP2012255007A5 true JP2012255007A5 (enExample) 2013-09-26
JP5774557B2 JP5774557B2 (ja) 2015-09-09

Family

ID=43531164

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523344A Pending JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤
JP2012176112A Expired - Fee Related JP5774557B2 (ja) 2009-08-05 2012-08-08 リポカリン突然変異タンパク質の制御放出製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012523344A Pending JP2013501033A (ja) 2009-08-05 2010-08-05 リポカリン突然変異タンパク質の制御放出製剤

Country Status (11)

Country Link
US (1) US20120201873A1 (enExample)
EP (2) EP2550958B1 (enExample)
JP (2) JP2013501033A (enExample)
KR (1) KR20120099371A (enExample)
CN (2) CN106139123A (enExample)
AU (2) AU2010280688A1 (enExample)
BR (1) BR112012002709A2 (enExample)
CA (1) CA2770149A1 (enExample)
IN (1) IN2012DN00407A (enExample)
RU (1) RU2012107812A (enExample)
WO (1) WO2011015634A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US9701732B2 (en) 2011-02-28 2017-07-11 Korea University Research And Business Foundation Fusion protein comprising albumin and retinol-binding protein
US10064915B2 (en) 2011-02-28 2018-09-04 Korea University Research And Business Foundation Fusion protein comprising albumin and retinol-binding protein
WO2012118323A2 (ko) * 2011-02-28 2012-09-07 고려대학교 산학협력단 알부민과 레티놀 결합 단백질의 융합 단백질
CA2833676C (en) * 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
WO2013068590A1 (en) * 2011-11-11 2013-05-16 Pieris Ag Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization
CA2860843C (en) * 2012-01-09 2021-03-23 Pieris Ag Methods for preventing, treating or diagnosing disorders
ES2604837T3 (es) 2012-02-02 2017-03-09 Esbatech - A Novartis Company Llc Formulación de liberación sostenida que contiene anticuerpos para administración ocular
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
JP5883539B2 (ja) 2012-03-16 2016-03-15 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｈｉｆ−１阻害剤の送達のための放出制御製剤
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN103394094B (zh) * 2013-07-16 2015-05-13 天津大学 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法
CN103360609B (zh) * 2013-07-16 2015-08-19 天津大学 一种双亲性的蛋白质-高分子键合体及其制备方法
WO2015104406A2 (en) * 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
EP3292148B1 (en) 2015-05-04 2024-01-24 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
CA3014406A1 (en) * 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia,and hormone-related tumors
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
HRP20000808A2 (en) 1998-06-08 2001-10-31 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
AU781336B2 (en) 1999-10-08 2005-05-19 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US9040664B2 (en) 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
CA2532302C (en) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
JP5165240B2 (ja) * 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US8598317B2 (en) * 2006-03-20 2013-12-03 Technische Universitaet Muenchen Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
DK2046820T3 (da) * 2006-08-01 2011-02-07 Pieris Ag Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf
US8178483B2 (en) * 2007-03-30 2012-05-15 Colgate-Palmolive Company Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
RU2009143560A (ru) * 2007-04-26 2011-06-10 Басф Се (De) Ферментативный способ получения микрокапсул
AU2008279879B2 (en) * 2007-07-26 2014-02-13 Aqtis Ip Bv Microparticles comprising PCL and uses thereof
EP2249809A1 (en) * 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
SG172737A1 (en) * 2008-01-30 2011-07-28 Pieris Ag Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinaseand methods for obtaining the same
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase

Similar Documents

Publication Publication Date Title
JP2012255007A5 (enExample)
WO2013096901A8 (en) Pharmaceutical formulations for fumagillin derivative-phf conjugates
EP3406347A3 (en) Xten conjugate compositions and methods of making same
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
WO2010033220A3 (en) Modified therapeutics peptides, methods of their preparation and use
MX2013014583A (es) Conjugados de proteina-polimero-farmaco.
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
NZ705384A (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
JP2018015005A5 (enExample)
JP2013519636A5 (enExample)
JP2010215657A5 (enExample)
UA114709C2 (uk) Кон'югат, що містить похідну оксинтомодуліну, fc-ділянку імуноглобуліну та непептидильний полімер, та його застосування
MX2023010178A (es) Conjugados de anticuerpo farmaco anti-cd70.
UA111820C2 (uk) Модифікований зв'язуючий протеїн, що інгібує взаємодію vegf-а-рецептора
JP2010534486A5 (enExample)
JP2014129395A5 (enExample)
JP2013507132A5 (enExample)
JP2010202664A5 (enExample)
EP2621480A4 (en) CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY
HK1209045A1 (en) Pegylated oxm variants
JP2011515499A5 (enExample)
WO2010064252A3 (en) Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
JP2013515745A5 (enExample)
BR112012015977A2 (pt) composto derivado de poli (ácido lático), método para preparar o composto derivado de poli (ácido lático), complexo do composto de derivado de poli (ácido lático), composição de liberação prolongada de droga, e, método para preparar a composição de liberação prolongada de droga